H1B Salary Data

Home › Employers › Rhodes Pharmaceuticals LP

Rhodes Pharmaceuticals LP: H-1B salaries and sponsorship

Rhodes Pharmaceuticals LP filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $94,466.

Applications (LCAs)3
Certified3
Employer addressWilson, NC
H-1B dependent employerNo
Median offered salary$94,466
Middle half of salaries$94,466–$127,802
10th–90th percentile$94,466–$147,804

Does Rhodes Pharmaceuticals LP sponsor H-1B visas?

Rhodes Pharmaceuticals LP filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 2, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Senior Regulatory Affairs Associate2$94,466
Senior Pharmaceutical Technology Scientist1$161,139

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20242$127,802
FY20251$94,466

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Senior Regulatory Affairs Associate$94,466
Level III
Raleigh, NCDec 2, 2024Dec 2, 2024Certified
Senior Regulatory Affairs Associate$94,466
Level III
North Providence, RIApr 19, 2024Sep 8, 2024Certified
Senior Pharmaceutical Technology Scientist$161,139
Level IV
Wilson, NCFeb 9, 2024Aug 10, 2024Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).